Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Neurotech Pharmaceuticals
With
The Lowy Medical Research Institute Limited
Protocol for Extended Follow-up of a Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients with Macular Telangiectasia Type 2 (MacTel)
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The participant must be offered sufficient opportunity to review the informed consent form, agree to the form's contents and sign the protocol's informed consent;
The participant must have bilateral MacTel;
Women of childbearing potential and all men must agree to use an effective form of birth control during the study;
Participant must be medically able to undergo ophthalmic surgery for ECT implant;
The participant's best-corrected visual acuity 64 letters or better (20/50 or better) in the study eye;
You may not be if
Participant is \< 21 years of age;
Participant is medically unable to comply with study procedures or follow- up visits;
Participant has evidence of ocular disease other than MacTel that may confound the outcome of the study (e.g., diabetic retinopathy with manifest macular edema, uveitis, etc.);
Participant has a chronic requirement (e.g., ≥ 4 weeks at a time) for ocular medications and/or has a diagnosed disease, that in the judgment of the examining physician, may be vision threatening or may affect the primary outcome (artificial tears are permitted);
Participant has evidence of subretinal neovascularization in either eye;
Participant has evidence of central serous chorio-retinopathy (CSR) in either eye;
Participant has evidence of pathologic myopia in either eye;
Participant has had a vitrectomy, penetrating keratoplasty, trabeculectomy or trabeculoplasty;
